Key result
An investigation of the FDA database was conducted to determine whether triptan monotherapy is associated with serotonin syndrome.
Why the study?
Is triptan monotherapy associated with serotonin syndrome?
Is triptan monotherapy associated with serotonin syndrome?
Answers are grounded in this paper and cite their sources.
This letter investigates whether triptan monotherapy alone can precipitate serotonin syndrome using FDA database reports.
To the Editor: Triptans are serotonin-receptor agonists used in the treatment of migraine headaches. When administered in combination with certain drugs, such as selective serotonin-reuptake inhibitors (SSRIs) and serotonin–norepinephrine reuptake inhibitors (SNRIs), triptans may precipitate the serotonin syndrome, a potentially life-threatening condition characterized by a triad of clinical manifestations — changes in mental status, autonomic hyperactivity, and neuromuscular abnormalities.1,2 The cause of the serotonin syndrome is related to altered serotonin synthesis, release, reuptake, metabolism, or receptor agonism.3 We investigated whether triptan monotherapy is associated with the serotonin syndrome by searching for such cases in the Food and Drug Administration's . . .
No takes yet. Share an insight, caveat, or question.
Soldin et al. (2008) conducted a letter in Migraine headaches / Serotonin syndrome. Triptan monotherapy was evaluated on Serotonin syndrome. An investigation of the FDA database was conducted to determine whether triptan monotherapy is associated with serotonin syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: